Share this article
Share this article
TUCSON, Ariz., April 1, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company s supply chain, serving as a final-stage manufacturing and sterilization center.
The new 120,000 square-foot facility will be built on approximately 32 acres at the northeast corner of Valencia and Kolb Road and is planned to be operational in mid-2022. BD plans to add approximately 40 new jobs, including engineers, scientists, quality control specialists and other skilled talent. Sun Corridor, Inc. projects that BD s investment will have a $122 million economic impact over the next 10 years.
Share this article
Share this article
NEW YORK, Feb. 22, 2021 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. The FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evidence that FDA is seeking to support a Biologics License Application (BLA). In addition, the FDA advised that this recommendation does not preclude Brainstorm from proceeding with a BLA submission.
NEW YORK, Feb. 22, 2021 /PRNewswire/ BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with. | February 27, 2021
BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study
USA - English
News provided by
Share this article
Share this article
NEW YORK, Dec. 18, 2020 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for progressive MS. The Phase 2 open-label clinical trial of repeat-dosing CSF-delivered autologous MSC-NTF cells (NurOwnâ) is being conducted at five clinical trial sites in the United States. Completed dosing of the Phase 2 progressive MS clinical trial is a major milestone for BrainStorm as we advance our goal to develop the NurOwn platform technology in neurodegenerative diseases, said Chaim Lebovits BrainStorm CEO. We are very thankful for the dedicated efforts of the investigators and their teams and to the patients who participa